Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateTimeSourceHeadlineSymbolCompany
30/01/202513:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
30/01/202513:00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceNASDAQ:KROSKeros Therapeutics Inc
24/01/202521:15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:KROSKeros Therapeutics Inc
21/01/202513:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
21/01/202513:00GlobeNewswire Inc.Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
15/01/202511:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
15/01/202511:30GlobeNewswire Inc.Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
10/01/202513:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
12/12/202411:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
12/12/202411:00GlobeNewswire Inc.Keros Therapeutics Announces Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
10/12/202400:30GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
03/12/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/12/202412:00GlobeNewswire Inc.Keros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
26/11/202413:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
26/11/202413:00GlobeNewswire Inc.Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
12/11/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
08/11/202421:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/11/202421:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
06/11/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/11/202413:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/11/202413:00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceNASDAQ:KROSKeros Therapeutics Inc
05/11/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
16/10/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
16/10/202412:00GlobeNewswire Inc.Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical OfficerNASDAQ:KROSKeros Therapeutics Inc
30/09/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
12/09/202412:00GlobeNewswire Inc.Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
03/09/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/09/202412:00GlobeNewswire Inc.Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
28/08/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
28/08/202412:00GlobeNewswire Inc.Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS